PAVE Peru Feasibility Study

Under the Partnership for Vivax Elimination (PAVE) and with funding from Unitaid, MMV is sponsoring a feasibility study in the department of Loreto, Peru. The study, which should run for approximately 25 months from April 2023, will examine the feasibility, acceptability, and cost implications of providing primaquine (PQ) or tafenoquine (TQ) after G6PD testing in real-world settings. The study is led by Universidad Peruana Cayetano Heredia (UPCH).

Loreto is Peru’s largest department covering almost one-third of the country's territory. It is also one of the most sparsely populated regions due to its remote location in the heart of the Peruvian Amazon Basin. In 2020, Loreto accounted for 84% of the country's 15,822 reported malaria cases.

Learn more about PAVE feasibility studies.